The stock of MannKind Corporation (NASDAQ:MNKD) closed at $ 1.32 gaining 4.76% in yesterday’s trading session. This industry leader has today made the much awaited announcement. It disclosed the appointment of Steven Binder as the new company’s Chief Financial Officer .He will be heading MannKind’s finance, accounting, and investor relations organization on a worldwide basis. He renders his services with immediate.
According to some top trusted sources, the top executive will be reporting directly to the Pharm.D Chief Executive Officer, Michael Castagna. The Company hopes that by adding him to its leadership team he will work closely with the rest of the leaders to propel the company to the highest levels of business success.
As a matter of fact, Mr. Binder will be quite instrumental to the company considering his over 25 working experience. He has done quite much in the healthcare industry and the company hopes to leverage on that experience to move towards its set business goals.
It is important to outline that the new official was privileged to work with Stryker Corporation (NYSE:SYK).This happens to be a top end global medical technology company where he was serving in the capacity of the company’s Chief Financial Officer and Vice President. It is based in Singapore and it is crucial to point out that he made a name for himself. He was a team player who remained much dedicated to work for all the years that he served.
Prior to joining Stryker Corporation, the official had served at Bristol-Myers Squibb Co (NYSE:BMY).This is an innovative global biopharmaceutical that has over the years remained much dedicated to developing top medical solutions to help the various patients globally. While here, he served as the vice president not forgetting that earlier he had served in some other positions. He helped steer the company forward in a major way.
While addressing board members, Mr. Binder stated “MannKind is well-positioned for future growth and I could not be more excited about being a part of this team. I believe Afrezza is an innovative product with great potential to improve the quality of life for diabetic patients.”